T 0363/18 (Treatment of hematologic malignancies/BIOGEN) of 30.07.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:T036318.20190730
- Date of decision
- 30 July 2019
- Case number
- T 0363/18
- Petition for review of
- -
- Application number
- 09002504.0
- IPC class
- A61K 39/395A61P 35/02
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
- Applicant name
- Biogen Inc.
- Opponent name
- Richter Gedeon Nyrt.
Pfizer Inc.(opposition withdrawn)
Novartis Pharma AG
Teva Pharmaceutical Industries Ltd
Sandoz AG
Genmab A/S
Celltrion, Inc.
Mundipharma International Ltd. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 76(1) (2007)
- Keywords
- All requests - claim 1 - added subject-matter (yes)
- Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.